Back to top
more

Cardinal Health (CAH)

(Delayed Data from NYSE)

$94.10 USD

94.10
1,891,045

-0.36 (-0.38%)

Updated Jul 12, 2024 03:59 PM ET

After-Market: $94.12 +0.02 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Profound Medical (PROF), Siemens Unite to Treat Prostate Cancer

Profound Medical (PROF) collaborates with Siemens to boost prostate cancer treatment procedures by combining their technologies.

Philips (PHG) Aids Diagnostic Imaging With Philips CT 5300

Philips (PHG) introduces AI-enabled Philips CT 5300 X-ray CT system, expanding its diagnostic imaging portfolio.

Best Momentum Stocks to Buy for March 1st

SPXC, CAH and TAST made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 1, 2023.

Myriad Genetics (MYGN) to Evaluate MRD Testing With New Pact

Myriad Genetics' (MYGN) MRD test is uniquely capable of detecting ctDNA at the lowest levels of detection, which is essential for a pan-cancer investigation.

Quest Diagnostics (DGX) Hurt by Lower Testing Sales, Competition

Quest Diagnostics (DGX) faces intense competition, primarily from LabCorp as well as other commercial laboratories and hospitals.

Veeva Systems (VEEV) Q4 Earnings Surpass Estimates, Margins Up

Veeva Systems' (VEEV) fiscal Q4 results reflect impressive performances by both segments.

Here's Why You Should Retain Omnicell (OMCL) Stock Now

Investors are optimistic about Omnicell (OMCL) moving closer to achieving its vision of Autonomous Pharmacy.

Bruker (BRKR) Inks Definitive Agreement to Acquire ELITechGroup

Bruker (BRKR) announces a share purchase agreement to acquire the molecular diagnostics innovator ELITechGroup.

Veradigm (MDRX) to Acquire AI Service Provider ScienceIO

Veradigm (MDRX) is set to acquire ScienceIO to benefit its Provider, Payer and Life Sciences businesses, offering highly differentiated and advanced products to its customers.

Cooper Companies (COO) Q1 Earnings Top, '24 Outlook Raised

Cooper Companies' (COO) first-quarter fiscal 2024 revenues reflect a solid segmental performance with improved adjusted earnings amid rising expenses.

New Strong Buy Stocks for March 1st

BMA, CAH, RCL, SPXC and RITM have been added to the Zacks Rank #1 (Strong Buy) List on March 1, 2023.

Best Income Stocks to Buy for March 1st

BMA, CAH and RITM made it to the Zacks Rank #1 (Strong Buy) income stocks list on March 1, 2023.

Inari Medical (NARI) Q4 Earnings Improve Y/Y, Gross Margin Down

Inari Medical's (NARI) fourth-quarter earnings miss, while sales match estimates. Gross margin improves while the company incurs losses at the operating level.

Merit Medical (MMSI) Q4 Earnings Top Estimates, Gross Margin Up

Merit Medical (MMSI) benefits from revenue growth in both segments and all product categories within its Cardiovascular unit in the fourth quarter.

Integra's (IART) Q4 Earnings Miss Estimates, Margins Down

Integra's (IART) Q4 revenues are impacted by the decline in the Tissue Technologies segment.

Cardinal Health, Inc. (CAH) Hits Fresh High: Is There Still Room to Run?

Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

DENTSPLY SIRONA (XRAY) Q4 Earnings Beat Estimates, Sales Up Y/Y

DENTSPLY SIRONA's (XRAY) Q4 revenues improve year over year. Challenging macro headwinds linger.

National Vision (EYE) Q4 Earnings Top Estimates, Margins Fall

National Vision's (EYE) Q4 adjusted comparable store sales growth is driven by ongoing strength within America's Best and Eyeglass World sales.

Nevro (NVRO) Gets FDA Nod for SI Fixation Without Lateral Screw

Nevro's (NVRO) SI joint fusion device, Nevro1, gets FDA clearance for the use of a lateral screw NevroFix.

Chemed (CHE) Q4 Earnings Surpass Estimates, Margins Expand

Chemed's (CHE) fourth-quarter 2023 performance reflects an improvement in VITAS' operational metrics.

3 Reasons Why Growth Investors Shouldn't Overlook Cardinal (CAH)

Cardinal (CAH) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Philips' (PHG) New Innovation to Boost Neurovascular Diagnosis

Philips (PHG) announces its latest Azurion neuro biplane system, which aims to improve the diagnosis of stroke and major neurovascular diseases. The system is designed for superior patient care.

Patterson Companies (PDCO) Misses on Q3 Earnings, Lowers EPS View

Patterson Companies' (PDCO) third-quarter fiscal 2024 results reflect an improvement in Dental Consumable sales, offset by lower Dental Equipment sales. Animal health sales appear weak.

Inogen (INGN) Q4 Earnings Miss Estimates, Gross Margin Improves

Inogen's (INGN) fourth-quarter earnings and revenues miss their respective consensus estimate. Gross margin expands while the company continues to incur losses at the operating level.

Masimo (MASI) Q4 Earnings Beat Estimates, Margins Decline

Despite strength in the Hearables category, Masimo's (MASI) overall fourth-quarter results reflect soft performances.